Investors hope Cyberonics
What analysts say:
- Buy, sell, or hold?: Analysts strongly back Cyberonics, with seven out of nine rating it a buy and the remainder rating it a hold. Analysts like Cyberonics better than competitor Heartware International overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $52.9 million in revenue this quarter. That would represent a rise of 12.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.30 per share. Estimates range from $0.28 to $0.31.
What our community says:
The majority of CAPS All-Stars see Cyberonics as a good bet, with 67.4% granting it an outperform rating. The majority of Fools (78.2%) agree with the All Stars and award it an outperform rating. The CAPS rating of five out of five stars for Cyberonics is far more upbeat than the community assessment.
Cyberonics' income has fallen year over year by an average of 30.6% over the past five quarters. Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Cyberonics now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.
More from The Motley Fool
Why Cyberonics, Inc. Vaulted Higher Today
Cyberonics announced better than expected results and a $2.7 billion merger with Sorin S.p.A.
Wednesday’s Top Health Care Stories: Valeant, Allergan, UnitedHealth Group, and Cyberonics
Valeant, Allergan, UnitedHealth Group, and Cyberonics could all make waves across the health care sector this Wednesday morning.
Did Cyberonics Squander Its Latest Sales Increase?
Keep your eye on margins.